Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults.

By S. Coughlin, E. Calle, L. Teras, Jennifer M. Petrelli, M. Thun. American Journal of Epidemiology, 2004

813 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes Mellitus (2008, neutral): “Meyerhardt et al,39 2003 (United States) C Colon 19881992 Not stage II, III; no en bloc resection, residual disease; ECOG 2; inadequate bone marrow, renal, or hepatic function; unavailable medical record; pregnant or lactating; other malignancy in the previous 3 y; previous chemotherapy, radiotherap”
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. (2009, background): “This is consistent with the known worse outcomes of diabetic versus nondiabetic patients with breast cancer.(6-8) In addition, although the pCR rate in the metformin group was threefold that in the nonmetformin group, there was no significant difference in the RFS or OS between these two groups.”
Dynamic interplay between the collagen scaffold and tumor evolution (2010, background): “These patients also have an elevated risk of developing tumors [35], suggesting that collagen glycation and the resulting ECM stiffening could be possible risk factors.”
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes (2009, background): “Type 2 diabetes is associated with an increased risk of mortality from a range of solid tumours, including cancers of the colon, breast and pancreas [1].”